Xian-Janssen And Nanjing Medical Resume Collaboration On Drug Distribution
This article was originally published in PharmAsia News
Executive Summary
Nanjing Medical and Xian-Janssen have ended their dispute over drug distribution (PharmAsia News, March 31, 2008), according to an insider, but the detailed compromise solution is not disclosed. The strained relations between the two firms have impacted Xian-Janssen's revenue, which dropped 20 to 30 percent in 2008. Based on the previous model, Nanjing Medical is now directly distributing Xian-Janssen's drugs in Fujian and Anhui provinces. However, Jiangsu is covered by Nanjing Huadong Medicine, which is Nanjing Medical's sister subsidiary under Nanjing Medical Industry (Group). The move shows Xian-Janssen's willingness to work indirectly with Nanjing Medical to avoid losing the latter's Jiangsu clients comprising 167 hospital pharmacies. (Click here for more - Chinese Language)
You may also be interested in...
No Winner In Nanjing Medical And Xian-Janssen Breakup
After breaking up their collaboration in 2007, Nanjing Medical and Xian-Janssen have made no progress in resuming their business negotiation. Xian-Janssen, the biggest OTC producer in China, has found another channel partner in Nanjing; Nanjing Medical on its part has taken up distributorship of alternative products. The standoff has not benefited either party. Xian-Janssen's key drug Motilium sees lower sales, while Nanjing Medical's newly released 2007 annual report shows that its pharmaceutical distribution profit growth only increased 0.21 percentage points compared to the previous year. Industry observers note that to achieve a win-win situation, pharmaceutical producers should give reasonable profit margins to distributors, which in turn should value the manufacturers' brand names. (Click here for more - Chinese Language)
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.